Joule First to Gain US EPA Clearance for Commercial Use of Modified Cyanobacteria for Fuel Production

Joule First to Gain US EPA Clearance for Commercial Use of Modified Cyanobacteria for Fuel Production

July 1, 2014

Bedford, MA – July 1, 2014 – Joule today announced that the US Environmental Protection Agency (EPA) has favorably reviewed the company’s Microbial Commercial Activity Notice (MCAN) for Joule’s first commercial ethanol-producing catalyst. This clears the catalyst for commercial use at the company’s demonstration plant in Hobbs, New Mexico. Notably, this also marks the first time that EPA has allowed the commercial use of a modified cyanobacterium.

Moderna Appoints Oncology Leader Dr. Stephen Kelsey as President of Onkaido

Moderna Appoints Oncology Leader Dr. Stephen Kelsey as President of Onkaido

July 1, 2014

Former Genentech executive to lead Moderna's first venture company, focused exclusively in novel biology for oncology drug development

Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer

Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer

June 24, 2014

Cambridge, Mass. – Editas Medicine, a transformative genome editing company, today announced the appointment of Katrine S. Bosley as chief executive officer. Ms. Bosley brings to Editas more than 20 years of experience in the biotechnology industry and has been a leader in emerging companies with broad platforms for innovative medicines.

Clinical Chemistry Study Reports on Use of T2MR to Evaluate Hemostasis in Whole Blood

Clinical Chemistry Study Reports on Use of T2MR to Evaluate Hemostasis in Whole Blood

June 23, 2014

-Results Suggest T2MR Has Potential to Provide Rapid and Sensitive Identification of Patients at Risk for Thrombosis and Bleeding-

Syros Pharmaceuticals Co-Founders’ Novel Approach to Cancer Regulation Published in Nature

Syros Pharmaceuticals Co-Founders’ Novel Approach to Cancer Regulation Published in Nature

June 23, 2014

Discovery further validates Syros’ proprietary gene control platform

BIND Therapeutics and Roche Collaborate on Discovery of Novel Nanomedicines

BIND Therapeutics and Roche Collaborate on Discovery of Novel Nanomedicines

June 19, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND's Accurin technology with Roche's proprietary therapeutic payloads and targeting ligands.

Moderna Named to CNBC Disruptor 50 List

Moderna Named to CNBC Disruptor 50 List

June 17, 2014

Messenger RNA TherapeuticsTM leader joins short list of major innovators for potential to transform the treatment of many diseases

Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout

Selecta Accelerates Immune Tolerance Therapeutics and Announces New Product Candidate, SEL-212, for Refractory and Tophaceous Gout

June 17, 2014

 Selecta's immune tolerance pipeline includes programs in gout, hemophilia A and food allergies

Selecta continues to advance key immune activation programs, with newly-announced funding totaling $9.35 million from the Bill & Melinda Gates Foundation and NIH/NIDA

Selecta Biosciences Enters Into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout

Selecta Biosciences Enters Into Exclusive License Agreement with 3SBio to Develop Drug Candidate to Treat Gout

June 17, 2014

3SBio’s pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory and tophaceous gout as well as tumor lysis syndrome

Selecta will combine pegsiticase with its novel immunomodulatory Synthetic Vaccine Particle (SVP™) platform to develop SEL-212, a treatment with improved efficacy and safety

Selecta Biosciences to Accelerate Program for Novel Dual Action Vaccine for Malaria

Selecta Biosciences to Accelerate Program for Novel Dual Action Vaccine for Malaria

June 17, 2014

Grant from the Bill & Melinda Gates Foundation to Leverage Synthetic Nanoparticle Vaccine Platform to Enable Potent, Durable, Dual-Action Vaccines